Explore Opportunities in Insurance & Pharmaceuticals - View Openings
September 23, 2026
On 3 June 2026, India's Central Drugs Standard Control Organisation (CDSCO) issued a circular that should matter not only to Regulatory Affairs teams, but also to pharmaceutical leaders responsible for Quality, Medical, People and hiring.
The 3 June 2026 CDSCO circular on implementation of a pharmacovigilance system under Schedule M did not introduce a completely new pharmacovigilance obligation. It reinforced an existing requirement under paragraph 6.11 of Schedule M: licensees must have a pharmacovigilance system for collecting, processing and forwarding reports of adverse drug reactions associated with medicines they manufacture or market. CDSCO also directed stakeholders to establish and maintain an effective system and stated that compliance may be verified during routine inspections and other regulatory activities.
For pharmaceutical employers, that has an important workforce implication. Pharmacovigilance cannot be treated simply as a back-office activity in which employees receive adverse-event reports, enter information into a database and meet reporting deadlines.
Those activities can form an important part of the function, but India's wider pharmacovigilance framework goes considerably further. The official Pharmacovigilance Guidance Document for Marketing Authorization Holders of Pharmaceutical Products, Version 2.0 covers areas including the Pharmacovigilance System Master File (PSMF), Individual Case Safety Reports (ICSRs), periodic safety reporting, Quality Management Systems (QMS), audits and inspections and Risk Management Plans (RMPs). It is guidance rather than a replacement for the underlying statutory provisions, but it provides a detailed view of how an effective pharmacovigilance system can operate in practice.
That means the hiring question needs to become more precise.
Instead of asking only, “Does this candidate have pharmacovigilance experience?”, we recommend asking: “What part of the pharmacovigilance system can this person competently operate, improve or oversee?”
Two professionals may each have five years of PV experience while bringing very different capabilities. That distinction is where better pharmacovigilance hiring begins.
India's Pharmacovigilance Programme of India (PvPI), coordinated through the Indian Pharmacopoeia Commission (IPC), defines its objectives far more broadly than adverse-event collection alone.
PvPI's stated objectives include creating a nationwide patient-safety reporting system, identifying and analysing safety signals, examining the benefit-risk profile of marketed medicines, generating evidence on medicine safety, supporting regulatory decision-making and communicating safety information to relevant stakeholders.
At company level, the CDSCO-IPC guidance similarly covers several distinct components of the PV system. This matters for recruitment because “pharmacovigilance experience” can mean very different things.
One professional may be highly experienced in case processing but have limited exposure to aggregate reporting. Another may have worked extensively on Periodic Safety Update Reports (PSURs) but have little experience of PV quality systems. A third may be strong in compliance, audits and inspection readiness without being a specialist medical reviewer.
None of those profiles is inherently weak. The problem arises when an employer publishes a vacancy asking simply for “five years of pharmacovigilance experience” without first defining which capability the organisation actually needs.
Effective PV recruitment therefore starts before the interview. It starts with defining the work.
Individual Case Safety Report processing is one of the foundations of pharmacovigilance, but processing cases is not the same as demonstrating judgement about the quality of those cases.
India's MAH guidance identifies critical PV activities including the collection, processing, management and quality control of safety information; follow-up for missing information; coding; classification; duplicate detection; evaluation; and timely transmission of ICSRs. It also identifies report completeness, case narratives, data management, causality assessment and signal management within the wider PV quality framework.
That gives employers a better way to assess experience. Rather than stopping at “Have you worked on ICSRs?”, the interview should explore how the candidate actually handled the work.
How did they deal with incomplete information? What did they do when clinically relevant details were missing? How did they approach follow-up? How did they distinguish information actually supplied by a reporter from later interpretation? What quality checks did they personally perform before a case moved through the workflow? How did they deal with inconsistent dates, coding decisions or potential duplicates?
The objective is not to turn every job interview into a regulatory examination. It is to establish whether the candidate understands the reasoning behind a reliable safety case, rather than merely recognising the process.
For junior professionals, the expected level of judgement will naturally differ from that expected of an experienced reviewer or manager. But even at an early-career level, accuracy, traceability, disciplined documentation and an understanding of why complete safety information matters should be visible.
Pharmacovigilance is a scientific and regulatory discipline, but it is also documentation-intensive. A safety record is valuable only if another qualified professional can understand what happened, where the information came from and how the relevant assessment was reached.
The Indian guidance specifically identifies case narrative and completeness of reporting within PV quality requirements. Written communication should therefore not be dismissed as a generic “soft skill”.
A capable PV professional needs to organise information coherently without adding facts that were never reported. They need to preserve chronology, distinguish source information from interpretation, recognise missing information and communicate clearly enough for subsequent medical, quality or regulatory review.
We recommend testing this capability during recruitment rather than assuming it from qualifications alone. An employer could, for example, present a short, anonymised scenario containing incomplete safety information and ask the candidate what they would document, what additional information they would seek, what they would escalate and what they would avoid assuming.
A carefully designed exercise of this kind can reveal considerably more about operating discipline than another generic interview question about strengths and weaknesses.
Case-level work is only one layer of pharmacovigilance. For roles involving products and Marketing Authorization Holders subject to periodic safety-reporting requirements, professionals may also need to understand how individual information contributes to a broader assessment of a medicine's safety profile.
CDSCO's Post Marketing Drug Safety Monitoring process describes a system in which PSUR submissions through the SUGAM portal are screened against predefined risk-based criteria. Higher-risk submissions may proceed to detailed expert review, with recommendations and subsequent regulatory actions tracked where required.
One distinction is important. The broad Schedule M obligation to maintain a pharmacovigilance system should not be treated as though every medicine, every licensee and every PV professional has identical PSUR responsibilities. Periodic safety-reporting requirements depend on the applicable regulatory framework, product and authorisation.
For positions where aggregate reporting genuinely forms part of the remit, however, employers should assess whether the candidate understands the difference between compiling information and interpreting it.
That means exploring what role the candidate has personally played in PSUR preparation or review, whether they have reconciled information from multiple sources, whether they understand how individual cases, cumulative safety information and exposure data contribute to aggregate assessment, and whether they have worked with Medical, Regulatory or other specialists when emerging information required further evaluation.
We do not recommend expecting every PV professional to be an aggregate-reporting specialist. We recommend ensuring that the assessment matches the work the person will actually perform.
One of PvPI's stated objectives is to identify and analyse new safety signals from reported cases. India also provides concrete examples of pharmacovigilance evidence progressing into regulatory action.
IPC maintains a public record of CDSCO orders issued based on PvPI recommendations. The 2026 entries include safety-related regulatory actions involving medicines such as carbimazole, doxycycline, cotrimoxazole and others.
This does not mean that every reported adverse event becomes a confirmed safety signal, nor should every case processor be expected to reach regulatory conclusions. But professionals working in PV should understand where their work sits within that wider chain.
For appropriate roles, employers should explore whether a candidate understands the difference between observing a potential pattern and establishing causality, why incomplete or duplicate information can affect assessment, when further investigation or escalation may be needed, and why uncertainty should be documented rather than hidden.
A strong candidate will not necessarily be the person who reaches a conclusion fastest. In medicine safety, recognising that the evidence is not yet sufficient can itself be a sign of sound professional judgement.
One of the most important parts of India's MAH pharmacovigilance guidance is its treatment of the Quality Management System.
The guidance describes QMS in PV as a framework of policies, procedures and systems necessary to ensure quality in the detection, assessment, understanding, evaluation and prevention of adverse events. It covers quality planning, adherence, quality control and assurance, and improvement through corrective and preventive measures.
It also states that MAHs should have sufficient numbers of competent, appropriately qualified and trained personnel to perform PV activities.
For employers, this broadens the definition of a good pharmacovigilance hire. A technically capable professional still needs to be able to operate within controlled processes.
At experienced levels, that may include understanding Standard Operating Procedures, deviations, Corrective and Preventive Actions (CAPA), training documentation, quality checks, change control, records, audit trails and inspection preparation.
For managers, the responsibility becomes broader. The leader needs to know not only whether work is getting completed, but whether the organisation can demonstrate that it is being completed consistently, through appropriate procedures, by trained people, with deficiencies identified and addressed.
That is why strong case-processing experience should not automatically be treated as evidence of management capability. Managing cases and managing the system behind those cases are different responsibilities.
The regulatory relevance of inspection readiness became especially visible in June 2026.
CDSCO's June 2026 circular on implementation of the pharmacovigilance system under Schedule M states that officers from CDSCO, State Licensing Authorities and Union Territory administrations may verify compliance with the relevant pharmacovigilance-system requirements during routine inspections and other regulatory activities.
The MAH guidance also addresses PV audits and inspections and describes their role in evaluating whether the pharmacovigilance system and its quality processes have been appropriately implemented and operated.
For senior recruitment, that creates a practical assessment question: Could this person explain and defend the PV process under scrutiny?
That does not mean every manager must already have personally led a regulatory inspection. But an experienced hire should understand what inspection readiness depends on: clear responsibilities, retrievable records, training evidence, process consistency, traceability, quality controls, data integrity and appropriate remediation when deficiencies are identified.
An interview can explore this through experience rather than theory. Ask about an audit finding, deviation, compliance problem or process failure the candidate encountered. What happened? How was the issue identified? What corrective action was taken? How was recurrence addressed? How did the team establish whether the corrective action had actually worked?
That conversation reveals much more about quality maturity than asking only, “Are you familiar with audits?”
PV does not operate in isolation.
The Indian guidance recognises multiple possible sources of safety information, including medical enquiries, website and email contacts, spontaneous reports, literature, digital media, patient-support programmes, regulatory authorities, contractual partners and market-research programmes. It also requires processes for relevant information to reach the pharmacovigilance function.
The guidance further identifies interaction between pharmacovigilance and product-quality-defect systems among critical processes, alongside communication of safety concerns with regulatory authorities.
This has direct recruitment implications. A PV professional may need to work with colleagues in Quality Assurance, Regulatory Affairs, Medical Affairs, Clinical functions, product-quality teams, medical-information channels, commercial functions, technology teams or external partners.
The capability being assessed should not simply be labelled “teamwork”. The more important question is whether the candidate understands how safety information needs to move through an organisation.
Can they recognise when information received outside the PV department has safety relevance? Can they explain requirements accurately to colleagues who are not pharmacovigilance specialists? Can they obtain missing information while maintaining traceability? Can they escalate an issue appropriately without overstating what the evidence proves?
For managers, the responsibility can include building processes and training that make safety escalation reliable beyond the immediate PV team. Cross-functional influence is therefore not merely a personality advantage. For many roles, it is part of pharmacovigilance effectiveness.
Technology deserves a place in modern PV recruitment, but employers should be careful not to convert every future-facing vacancy into an AI vacancy.
There is clear institutional interest in this area. In August 2026, the Indian Pharmacopoeia Commission held a brainstorming session on AI-powered pharmacopoeia standards development and pharmacovigilance practices, bringing together participants from the pharmaceutical industry, regulatory authorities, Contract Research Organisations, academia and technology.
That is meaningful evidence that AI-enabled approaches are being actively explored within India's pharmaceutical safety and regulatory ecosystem. It is not evidence that AI has already replaced conventional pharmacovigilance processes across the Indian industry.
The hiring implication should therefore be measured.
For junior professionals, digital readiness may include confidence with structured data, electronic workflows, safety databases and the ability to learn unfamiliar systems. For experienced professionals, it may extend to areas such as process controls, system validation, data governance, change management and understanding the risks created when automation enters regulated workflows.
But the underlying questions remain human ones. Is the information reliable? Is anything important missing? Does the automated output make sense in context? When is scientific or medical judgement required? Can the decision and its supporting information be traced?
Technology can strengthen a process. It does not remove the accountability attached to that process.
The response to a more developed PV environment should not be an advertisement seeking one candidate who can do everything.
Pharmacovigilance contains multiple areas of work. Depending on the organisation, a role may focus primarily on ICSR processing, medical review, literature surveillance, aggregate reporting, signal management, PV quality, compliance, risk management, operations or leadership.
The hiring process should reflect that reality.
If the problem is weak case quality, the assessment should concentrate on case-processing judgement, follow-up, documentation and quality control. If the role owns aggregate reporting, the interview should establish genuine aggregate-report experience. If the organisation needs a PV quality specialist, experience with SOPs, quality systems, deviations, CAPA, audits and inspection preparation becomes more relevant.
For leadership positions, the emphasis changes again. Employers need to understand whether the candidate can oversee governance, people capability, training, quality, cross-functional coordination and the effectiveness of the wider PV system.
A vacancy does not become sophisticated simply because it contains a long list of PV acronyms. A strong job description maps competencies to the work for which the person will actually be accountable.
Candidates can learn definitions before an interview. It is considerably harder to manufacture evidence of how they think.
For that reason, we recommend moving beyond questions that simply establish whether someone recognises terms such as ICSR, MedDRA, PSMF, PSUR, QMS, CAPA, RMP or signal management.
Instead, explore how those concepts appeared in the candidate's actual work. For a case-processing professional, discuss an incomplete or ambiguous report. For a quality professional, explore a deviation, audit finding or corrective action. For someone working in aggregate reporting, ask which elements they personally owned. For experienced hires, discuss a deadline risk, recurring quality issue or cross-functional failure.
For managers, ask how they determined whether training actually improved performance rather than simply confirming that training occurred.
Across these conversations, three questions are particularly useful: What did you personally do? What judgement did you apply? How did you know the output met the required standard?
Those questions help separate genuine competence from simple exposure.
The same discipline should apply to a pharmacovigilance CV.
A CV should not become a catalogue of acronyms. “Worked on ICSRs, MedDRA and PSURs” tells an employer very little about the person's actual responsibility.
A stronger profile makes the scope clear. A candidate might accurately describe experience in case intake, follow-up, narrative preparation, coding, quality review or literature surveillance. Another might have supported aggregate reporting, safety-data reconciliation, quality systems, SOP development, CAPA tracking, signal review or audit preparation. A senior professional may have overseen training, compliance, vendors, inspection readiness or broader safety governance.
The important word is accurately.
Exposure should not be presented as ownership. Supporting a PSUR is not necessarily the same as authoring or leading one. Participating in inspection preparation is not the same as leading an inspection. Providing input into signal review is not the same as owning signal management.
Precision improves credibility.
Continuous development also matters. The National Coordination Centre-PvPI at IPC continued formal pharmacovigilance capability-building during 2026, including its 37th Skill Development Programme on Pharmacovigilance in June and 38th Skill Development Programme on Pharmacovigilance in August.
The lesson for candidates is not to accumulate certificates merely to lengthen a CV. It is to keep technical knowledge aligned with the responsibilities they want to take on next.
The timing of this discussion is particularly relevant.
India's sixth National Pharmacovigilance Week was held from 17–23 September 2026 under the theme “Promoting Rational Use of Medicines through Pharmacovigilance – A Step Towards Safer Healthcare.” IPC connected pharmacovigilance and rational medicine use directly with medication safety and better patient outcomes. Read the IPC update on National Pharmacovigilance Week 2026.
That brings the discussion back to why the function exists.
Pharmacovigilance is not valuable because an organisation can produce more safety paperwork. It is valuable because information collected after medicines reach wider use can improve understanding of their safety profile, identify potential risks and support appropriate clinical and regulatory action.
The June 2026 CDSCO circular has made the requirement for an effective PV system particularly visible. For employers, the workforce conclusion is not that every pharmaceutical company suddenly needs the same type of pharmacovigilance professional. It is that PV capability needs to be defined more carefully.
A strong PV team is not necessarily the team with the largest number of employees carrying “pharmacovigilance” in their job titles. It is a team with the right combination of people to collect reliable safety information, process it accurately, maintain appropriate quality controls, recognise when escalation is required, support applicable regulatory obligations, communicate across functions and demonstrate how the system operates when scrutinised.
That should influence the way organisations recruit.
Before opening the next PV vacancy, employers should define the actual problem the person needs to solve. A requirement for additional case-processing capacity is different from a requirement to improve case quality. Both are different again from a need for aggregate-reporting expertise, PV quality, audit readiness, signal-management support, cross-functional safety governance or team leadership.
That distinction should shape the job description, interview design and level of experience required.
We recommend testing judgement rather than acronym recall and assessing documentation discipline alongside technical knowledge. For management positions, the question is whether the candidate can maintain an effective system through people, processes, controls, training and cross-functional coordination—not simply whether they have spent enough years inside a PV department.
The same principle applies when technology enters the discussion. Knowing the language of AI is not enough. Employers should understand whether a candidate can use technology responsibly inside a controlled medicine-safety process, recognise the limits of automated outputs and preserve the quality and traceability that regulated work requires.
For candidates, the principle is equally straightforward. Do not rely only on the number of years beside your PV job title. Make clear which part of the pharmacovigilance system you can genuinely operate, the level of responsibility you have held and how your work contributed to quality and medicine safety.
As India's regulatory framework continues to reinforce effective pharmacovigilance systems, the distinction between experience on paper and demonstrated capability becomes increasingly important.
The required skills depend on the role. They may include ICSR processing and quality, follow-up, documentation, coding, aggregate reporting, signal literacy, QMS knowledge, audit and inspection readiness, cross-functional communication and appropriate digital capability.
Employers should define which of these capabilities the position genuinely requires rather than using “PV experience” as a catch-all criterion. The CDSCO-IPC Pharmacovigilance Guidance Document for Marketing Authorization Holders provides useful regulatory context for many of these areas.
No. Case processing is an important component, but India's pharmacovigilance framework also encompasses quality systems, signal management, periodic safety reporting where applicable, risk management, documentation, audits, inspections and safety communication.
No. PSUR responsibilities depend on the role and applicable product and regulatory requirements. Employers should assess aggregate-reporting experience when it is genuinely part of the position rather than treating it as a universal requirement.
The current evidence does not support such a conclusion. IPC is actively exploring AI-enabled applications in pharmacovigilance, including through its 2026 session on AI-powered pharmacopoeia standards development and pharmacovigilance practices, but technology remains part of a regulated system that still depends on data quality, scientific judgement, appropriate controls and human accountability.
At PharmaSolution Placement, we are a specialist Indian recruitment firm focused on the Pharmaceutical and Insurance sectors. We work with employers to understand the capability a role genuinely requires and with professionals looking for relevant opportunities to advance their careers.
If you are considering your next career move, Explore All Jobs, view current Pharmaceutical Opportunities or Submit Your CV.
If you are an employer with a recruitment requirement, Submit a Job or Contact Us to discuss your hiring needs.
.png){kind=icon}
.png){kind=icon}
